Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAD Induction in Untreated Multiple Myeloma
NCT00872521Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2009
- Primary completion
- Mar 2011
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall Response Rate at 84 days. Started Jan 2009; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00872521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00872521.